Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.
Clare BuckeridgeNikolaos TsamandourasSantos Carvajal-GonzalezLisa S BrownMartha Hernandez-IllasAditi R SaxenaPublished in: Diabetes, obesity & metabolism (2024)
gov identifier: NCT04305587, NCT05158244.
Keyphrases
- placebo controlled
- type diabetes
- small molecule
- double blind
- insulin resistance
- phase iii
- phase ii
- protein protein
- glycemic control
- clinical trial
- metabolic syndrome
- study protocol
- weight loss
- high fat diet induced
- phase ii study
- physical activity
- case control
- pulmonary artery
- weight gain
- open label
- randomized controlled trial
- skeletal muscle
- squamous cell carcinoma
- adipose tissue
- pulmonary hypertension